Celgene Corp. (CELG)

100.95
0.56 0.56
NASDAQ : Health Technology
Prev Close 100.39
Open 100.50
Day Low/High 100.40 / 101.19
52 Wk Low/High 58.59 / 100.96
Volume 2.64M
Avg Volume 3.61M
Exchange NASDAQ
Shares Outstanding 708.74M
Market Cap 71.28B
EPS 5.70
P/E Ratio 13.78
Div & Yield N.A. (N.A)
On Halloween, Here Are 5 Scary Stock Charts: Market Recon

On Halloween, Here Are 5 Scary Stock Charts: Market Recon

The fundamentals are there, supported by earnings. Let's look at the charts.

Cramer: We're Seeing the Best of Times and the Worst of Times at the Same Time

Cramer: We're Seeing the Best of Times and the Worst of Times at the Same Time

It depends on which aisle of the stock market you're on.

3 Small-Caps on My Growth Stock Radar

3 Small-Caps on My Growth Stock Radar

LGI Homes, ANI Pharmaceuticals and Sonus Networks are worth considering.

The Art and Science of Buying Dips

The Art and Science of Buying Dips

This can produce big gains, but what if the stock keeps dipping?

3 Biotech Stalwarts Just Can't Bio a Break

3 Biotech Stalwarts Just Can't Bio a Break

The stocks of Amgen, Celgene and Gilead Sciences all took hits after posting quarterly results.

There Is Sound Fundamental Reasoning Behind the Positivity: Market Recon

There Is Sound Fundamental Reasoning Behind the Positivity: Market Recon

The ECB's super dovish message was good for the markets.

Recently Merged DowDuPont Powers Dow Higher

Recently Merged DowDuPont Powers Dow Higher

Shares of DowDuPont jumped after issuing preliminary third-quarter results.

Two-Sided Market

An observation:  Despite being within 1% of the all-time high in the S&P Index, this week's feature was a number of investment potholes --relatively large sized individual fundamental disappointments followed by marked stock price drops. Celgene , B...

Cramer: Stock Market's 'Safety Dance' Has Reversed

Cramer: Stock Market's 'Safety Dance' Has Reversed

What was dangerous is now safe, what was safe is now risky.

Carpet Sweepers

A frequent theme of mine is the lack of follow-up and accountability by commentators and "talking heads" in the media of the many ideas that have soured.  Losers are part of the game -- and those who don't confess to mistakes are either lying or, as...

Video: Jim Cramer on Twitter, Comcast, Ford, Southwest Air, NXP and Celgene

Video: Jim Cramer on Twitter, Comcast, Ford, Southwest Air, NXP and Celgene

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Thursday's trending stocks.

Video: Jim Cramer: I Don't Want to Panic and Sell Celgene

Video: Jim Cramer: I Don't Want to Panic and Sell Celgene

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't advise panicking over Celgene.

Market Action Isn't So Hot Despite What You May Hear

Market Action Isn't So Hot Despite What You May Hear

Breadth is positive, but pockets of momentum are very limited.

Buying More Allergan on Biotech Weakness

This morning I added to Allergan on weakness in biotech -- a true contrarian and counterintuitive bet considering the struggles of Celgene et al. However, I am still only medium in size in my AGN position.

Celgene Falls After Updates to 2017 Guidance, 2020 Targets -- Biotech Movers

Celgene Falls After Updates to 2017 Guidance, 2020 Targets -- Biotech Movers

The Summit, N.J.-based firm on Oct. 26 unveiled third-quarter results and updated its 2017 outlook and financial targets for 2020.

Praise by Name, Criticize by Category

As an observation, I find -- and this is characteristic of a mature bull market -- that many investors, strategists, commentators and talking heads are just taking shots in the dark on stocks these days and are not adjusting their outlooks for chang...

Has Falling Knife Celgene Hit the Floor? Not Yet

Has Falling Knife Celgene Hit the Floor? Not Yet

Celgene's stock price movement is ugly indeed.

Celgene Disappoints and Takes a Hit

Celgene is down around $13 in premarket trading after disappointment over its third-quarter results.    This stock has been widely heralded on "Fast Money" and elsewhere, mostly on technical grounds.   But I must say, our Bobby Lang showed a lot of ...

Remember That Bumps in the Road Are Normal: Market Recon

Remember That Bumps in the Road Are Normal: Market Recon

The forces that artificially impacted the marketplace return to normal; so will the marketplace itself.

Don't Panic About Biotech

Don't Panic About Biotech

Diversification is absolutely critical when investing in this sector.

My (Brief) Takeaways and Observations

With thirty minutes to go: * Watching CNBC and the rest of the business media, one would conclude that "everyone is in the pool." It is, as one talking head just declared..."a buy/buy scenario." (Enough said/written). * The bond market's decline was...

Celgene Down After Pulling Plug on Crohn's Disease Drug Study -- Biotech Movers

Celgene Down After Pulling Plug on Crohn's Disease Drug Study -- Biotech Movers

The Summit, N.J.-based firm said Thursday that it was discontinuing the GED-0301 (mongersen) Phase 3 Revolve study in Crohn's disease and the extension trial.

Celgene Cut to Neutral at Baird

Celgene: Look Beyond Any Short-Term Weakness

Celgene: Look Beyond Any Short-Term Weakness

CELG could dip and then post longer-term gains.

'Zone' In on This Celgene Setup

'Zone' In on This Celgene Setup

Look at this recent pullback as an opportunity for a buy-side entry.

Are You Patient Enough With Options?

Are You Patient Enough With Options?

You have options when trading options, so don't give up your leverage or advantage too soon.

My Takeaways and Observations

"While options can give market participants the protection they are intended to provide, they can also increase the degree of a counter move, once it gets going, as those who wrote the protection scramble to unwind their own exposure." -- Kass Diary...

Celgene and Biogen Analyst Moves Are 'Useless,' Jim Cramer Says

Celgene and Biogen Analyst Moves Are 'Useless,' Jim Cramer Says

Morgan Stanley analysts upgraded shares of Biogen and downgraded shares of Celgene over concerns of generic drug pressures. TheStreet's Jim Cramer called these moves "useless."